Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. - Wikidata - awgldk - TriplyDB

Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite.

Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite.

http://www.wikidata.org/entity/Q43964770

about

Once-yearly zoledronic acid in hip fracture prevention Innovative Target Therapies Are Able to Block the Inflammation Associated with Dysfunction of the Cholesterol Biosynthesis Pathway SLC transporters as therapeutic targets: emerging opportunities Bisphosphonates: from bench to bedside Drug screening on Hutchinson Gilford progeria pluripotent stem cells reveals aminopyrimidines as new modulators of farnesylation.Microglial depletion using intrahippocampal injection of liposome-encapsulated clodronate in prolonged hypothermic cardiac arrest in rats.Clodronate exerts an anabolic effect on articular chondrocytes mediated through the purinergic receptor pathway.Direct antitumour activity of zoledronic acid: preclinical and clinical data.Anti-Tumor Activity and Immunotherapeutic Potential of a Bisphosphonate Prodrug.Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.Predictors of atypical femoral fractures during long term bisphosphonate therapy: a case series & review of literature The kd/kd mouse is a model of collapsing glomerulopathy The alveolar macrophages in asthma: a double-edged sword.Bisphosphonates pathway.Discoveries, drugs and skeletal disorders.Differences between the bisphosphonates for the prevention and treatment of osteoporosis.The Chemical and Physical Properties of Poly(ε-caprolactone) Scaffolds Functionalised with Poly(vinyl phosphonic acid-co-acrylic acid).Bisphosphonamidate clodronate prodrug exhibits potent anticancer activity in non-small-cell lung cancer cells Modelling circulating tumour cells for personalised survival prediction in metastatic breast cancer Bisphosphonates significantly increase the activity of doxorubicin or vincristine against canine malignant histiocytosis cells.Discovery, clinical development, and therapeutic uses of bisphosphonates.Modulating P2X7 Receptor Signaling during Rheumatoid Arthritis: New Therapeutic Approaches for Bisphosphonates Efficacy and Safety of Zoledronic Acid and Pamidronate Disodium in the Treatment of Malignant Skeletal Metastasis: A Meta-Analysis Systemic macrophage depletion inhibits Helicobacter bilis-induced proinflammatory cytokine-mediated typhlocolitis and impairs bacterial colonization dynamics in a BALB/c Rag2-/- mouse model of inflammatory bowel disease.Bisphosphonates as potential adjuvants for patients with cancers of the digestive system.Mitochondrial permeability transition pore as a selective target for anti-cancer therapy Effect of long-term oral bisphosphonates on implant wound healing: literature review and a case report.Depletion of resident alveolar macrophages does not prevent Fas-mediated lung injury in mice.Immunomodulating role of bisphosphonates on human gamma delta T cells: an intriguing and promising aspect of their antitumour activity.Potential applications of biphosphonates in dental surgical implants.Evaluation of the predisposing factors and involved outcome of surgical treatment in bisphosphonate-related osteonecrosis of the jaw cases including bone biopsies.Zoledronic acid inhibits macrophage/microglia-assisted breast cancer cell invasion Pharmacokinetic profile of bisphosphonates in the treatment of metabolic bone disorders.Clodronate acts on human osteoclastic cell proliferation, differentiation and function in a bioreversible manner.Bisphosphonamidate clodronate prodrug exhibits selective cytotoxic activity against melanoma cell lines.Toll-like receptor 9 expression is associated with breast cancer sensitivity to the growth inhibitory effects of bisphosphonates in vitro and in vivo.Bisphosphonates and atypical subtrochanteric fractures of the femur.Anticancer effect of bisphosphonates: new insights from clinical trials and preclinical evidence.Targeting the mitochondrial permeability transition: cardiac ischemia-reperfusion versus carcinogenesis.Physiology of the aging bone and mechanisms of action of bisphosphonates.

P2860

Q24657667-15CF0088-0E13-4E5D-9892-07AE87FE9F16 Q26771260-724A32B3-C9DA-4D41-95C9-24D64DFFCF84 Q27014726-D4441055-8444-405C-8500-64697FF9B5C2 Q28251212-FFCEF4B4-0885-4473-B24C-3E923999E2DE Q30846580-3605000B-2892-4D0F-8F2A-E3BF86F7C679 Q33668297-97C39562-3B08-4A61-A1E5-3F194E877413 Q33750999-C8E0F328-F168-4679-925D-34B0D8683DBC Q33850938-1C658D79-F1AE-4F6B-B236-142FEC11871B Q33920919-949DFB43-3FFF-4183-AF4E-16021264A5C2 Q34009569-0F565426-A7B4-42F9-9631-37AFDEC0B784 Q34272136-DC0E6E99-8E94-4EA1-A983-9385E40FAC4B Q34547622-61B69FCC-7ABA-48E6-860E-224C70C5479C Q34641655-474E9C4F-8B80-41FB-9204-87BEC8E5F7E7 Q34905878-4629EB2E-7E0F-4DDA-B90F-8ABF420B04C1 Q34932153-66E11DCF-BC54-4599-BC79-235E70A63DA3 Q35166767-F119E3B5-8580-444D-AD39-A4FBB9ECAE5A Q35231853-3C5161CE-85E9-4CEB-832A-6EB49F115135 Q35285026-7562B377-05FD-4FEE-B540-006AE6DCA290 Q35610546-D342F4E4-E46D-44EF-B450-36C9DFD3342F Q35754021-15E74318-A78D-4249-9D80-9CAB83AE7D9A Q36065420-285142C7-3C84-4754-8D98-9CB4C679F700 Q36101996-731F0FC9-39E6-40A1-902F-879096D94268 Q36206819-F1234B78-26E5-4B43-8D9E-42DCBF849A52 Q36396805-206EEA47-5950-4F03-AF89-3AE50C075DDC Q36471673-C04782A9-214B-4B31-BCA7-D4788BB86D88 Q36668047-26FBC4CC-B289-4498-A437-AA0C55FDFA87 Q36750128-5E8505BB-6382-47B9-9618-693257221526 Q36846464-581D4321-F4DF-4C19-AC16-676B379EC04E Q36871994-70D479AB-8A4F-4D7E-A14A-D5DF9EC3CB70 Q36946054-2798C22F-225E-43EF-ADCA-0AEC98CFE562 Q37227563-D48EDBA4-F8D6-4922-98B5-F06CF67704D7 Q37299295-3071ABD3-48C4-4ACC-9A4B-4B10FF187372 Q37430269-773FE5A5-72CD-4830-AE8A-254AF8831647 Q37430521-8EBF6379-8CB0-4F6A-91B2-827805823FDD Q37623726-496FD388-796C-4241-8180-438DAC3E54CD Q37699431-EDB9E1C9-3463-4F8A-AC60-076F5C7F23B9 Q37733851-4829B353-8579-4FD6-B590-046405A4CC7D Q37845836-E556B4DA-96ED-4B0C-9E4B-E3AF253BA6DE Q37862534-40A4D9A8-DD5D-478C-970F-F18D97CE292E Q37892992-A63A4D73-7E5B-408E-BB54-117A3A7F2515

P2860

Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite.

http://www.wikidata.org/entity/Q43964770

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh-hant

name

Further insight into mechanism ...... adenine-containing metabolite.

@en

Further insight into mechanism ...... adenine-containing metabolite.

@nl

type

label

Further insight into mechanism ...... adenine-containing metabolite.

@en

Further insight into mechanism ...... adenine-containing metabolite.

@nl

prefLabel

Further insight into mechanism ...... adenine-containing metabolite.

@en

Further insight into mechanism ...... adenine-containing metabolite.

@nl

P1433

Q43964770-8E601ABB-0A11-4ECC-8A74-CFA1012CB1B9

P1476

Q43964770-A7227B87-2DFD-4029-A347-783BA3981B91

P2093

Q43964770-1AE41212-6148-440E-A0AB-9882AFF47FA4

Q43964770-6B39BFC4-27D7-439B-AEE7-0C6BD6E1221C

Q43964770-6FF8E716-4EFB-46F0-BF23-FED8624F60C1

Q43964770-93D4C23A-5B11-469E-B6FA-2C56E81285D0

Q43964770-9885A460-BA21-41AE-9345-B704E24A3E9C

Q43964770-9929C371-5FD9-4A70-B609-B866D4AED826

Q43964770-C63ED0A9-5D9D-4B1C-A7DC-35DDF855138D

P304

Q43964770-FABDFA04-FF92-429B-B2D1-8852031C57DD

P31

Q43964770-D8EE6096-56D8-4387-92B0-4A1B902288D7

P356

Q43964770-0A27C05A-4609-48D0-B96A-083620697B83

P433

Q43964770-71D0467C-0621-443E-A567-FF9D6179D4B5

P478

Q43964770-8CE7EFB0-7B1B-46D8-AA21-9256ECBCA5F3

P50

Q43964770-3A7F0AFD-2688-4FA2-BD32-731FF00D8A7F

Q43964770-B722EBCE-3E41-4EA5-A89E-12021AF5D788

P577

Q43964770-019E3A27-8A78-45A7-8418-A5C1CDDC48B3

P5875

Q43964770-E24F0A08-2452-42AB-ABFD-A70DEEC2F6F7

P698

Q43964770-1FBE3541-9B9E-470F-B136-0E1E31DDE323

P356

P1433

Molecular Pharmacology

P1476

Further insight into mechanism ...... adenine-containing metabolite

@en

P2093

Alex Azhayev

http://www.w3.org/2001/XMLSchema#string

H Kalervo Väänänen

http://www.w3.org/2001/XMLSchema#string

Ilmo E Hassinen

http://www.w3.org/2001/XMLSchema#string

Juha P Näpänkangas

http://www.w3.org/2001/XMLSchema#string

Jukka Mönkkönen

http://www.w3.org/2001/XMLSchema#string

Kari V Ylitalo

http://www.w3.org/2001/XMLSchema#string

Maarit Kellinsalmi

http://www.w3.org/2001/XMLSchema#string

P304

1255-1262

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1124/MOL.61.5.1255

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

61

http://www.w3.org/2001/XMLSchema#string

P50

Petri Lehenkari

Michael J. Rogers

P577

2002-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11406610

http://www.w3.org/2001/XMLSchema#string

P698

11961144

http://www.w3.org/2001/XMLSchema#string